Panacea Biotec is currently trading at Rs. 270.40, up by 13.50 points or 5.25% from its previous closing of Rs. 256.90 on the BSE.
The scrip opened at Rs. 262.90 and has touched a high and low of Rs. 279.00 and Rs. 260.00 respectively. So far 69004 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 302.40 on 29-Nov-2017 and a 52 week low of Rs. 125.70 on 17-Jan-2017.
Last one week high and low of the scrip stood at Rs. 279.00 and Rs. 231.00 respectively. The current market cap of the company is Rs. 1610.89 crore.
The promoters holding in the company stood at 74.07%, while institutions and non-institutions held 0.03% and 25.90% respectively.
Panacea Biotec has entered into two long term agreements with Serum Institute of India (SII) and SII’s wholly owned subsidiary, Bilthovan Biologicals B.V. (BBIO). Under the collaboration, SII is entitled to manufacture & sell fully liquid Whole cell Pertussis (wP) and Salk based Injectable Polio Vaccine (IPV) based Hexavalent vaccine (DTwP-HepB-Hib-IPV) developed & commercialized by Panacea Biotec, a first of its kind in this category.
Under the collaboration, Serum Institute of India will ensure supply of IPV bulk to Panacea Biotec, an important constituent of the Hexavalent vaccine, from its wholly owned subsidiary BBIO, a bioengineering and pharmaceutical company, registered in The Netherlands having technology and expertise for making the IPV, earlier possessed by only 3 other vaccine manufacturers in the World.
Panacea Biotec is a leading biotechnology company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and leading Biotechnology Companies in India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: